key: cord-0782797-fyf3kny3
authors: Gundlapalli, Adi V; Salerno, Reynolds M; Brooks, John T; Averhoff, Francisco; Petersen, Lyle; McDonald, L Clifford; Iademarco, Michael F
title: SARS-CoV-2 Serologic Assay Needs for The Next Phase of U.S. COVID-19 Pandemic Response
date: 2020-11-17
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofaa555
sha: 0be9b388982181a7be6a599e2686b80de0f3c2ee
doc_id: 782797
cord_uid: fyf3kny3

BACKGROUND: There is a need for validated and standardized SARS-CoV-2 quantitative IgG and neutralization assays that can be used to understand the immunology and pathogenesis of SARS-CoV-2 infection and support the COVID-19 pandemic response. METHODS: Literature searches were conducted to identify English language publications from peer-reviewed journals and pre-prints from January 2020 through October 12, 2020. Relevant publications were reviewed for mention of IgG or neutralization assays for SARS-CoV-2, or both, and the methods of reporting assay results. RESULTS: Quantitative SARS-CoV-2 IgG results have been reported from a limited number of studies; most studies used in-house laboratory-developed tests in limited settings, and only two semi-quantitative tests have received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA). As of October12, 2020, there are no neutralization assays with FDA EUA. Relatively few studies have attempted correlation of quantitative IgG titers with neutralization results to estimate surrogates of protection. The number of individuals tested is small compared to the magnitude of the pandemic and persons tested are not representative of disproportionately affected populations. Methods of reporting quantitative results are not standardized to enable comparisons and meta-analyses. CONCLUSIONS: Lack of standardized SARS-CoV-2 quantitative IgG and neutralization assays precludes comparison of results from published studies. Inter-assay and inter-laboratory validation and standardization of assays will support efforts to better understand antibody kinetics and longevity of humoral immune responses post-illness, surrogates of immune protection, and vaccine immunogenicity and efficacy. Public-private partnerships could facilitate realization of these advances in the United States and world-wide.

M a n u s c r i p t

In response to the COVID-19 pandemic, a number of SARS-CoV-2 nucleic acid amplification tests, antigen-based tests, and serologic assays have been developed and used extensively worldwide for diagnostic, screening, and surveillance purposes. Since the start of the pandemic, the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUA) for nearly 200 assays to support the COVID-19 response in the United States 1 . The overwhelming majority of these FDA-authorized assays are nucleic acid amplification tests in the form of real-time reverse transcriptase polymerase chain reaction (rRT-PCR) assays for testing respiratory specimens (nasal and nasopharyngeal swabs). Recently, the FDA has also issued EUAs for rapid testing platforms that detect viral antigens. Since April 2020, serologic assays to detect antibodies produced against SARS-CoV-2 have become widely available in the United States.

In order to apply SARS-CoV-2 serologic testing strategies to inform public health interventions and individual patient management, serologic correlates of protection against SARS-CoV-2, in terms of antibody type and concentration, and duration of immunity conferred must be clearly established. These outcomes of individual and public health significance must be determined in association with clinical and epidemiologic data on various outcomes, such as decreased transmission, decreased duration and severity of illness, improved outcomes, prevention of re-infection, and when available, the efficacy of vaccine candidates to protect against or decrease severity of primary infection. For broad understanding and consensus building of correlates of protection, these studies would need to include participants that are demographically diverse in terms of age group, sex, and race/ethnicity, as well as populations disproportionately affected by Historically, for other bacterial and viral pathogens, such data have been derived from vaccine studies for vaccine-preventable diseases 2,3 , from studies of natural history of infection for diseases that are not vaccine preventable, or from animal models. As our knowledge of the natural history of SARS-CoV-2 and associated illness is currently evolving, and vaccine candidates remain in development, we must base our assessment of serological correlates of protection on peer-reviewed reports of infection and reinfection, convalescent plasma therapy trials, and vaccine candidate studies. There is limited value in lessons learned from the SARS outbreak in 2003 4,5 and the ongoing outbreak of Middle East Respiratory Virus (MERS) 6 ; for example, the timing and longevity of IgG and neutralizing antibodies to these viruses has been variable (ranging from months to years), SARS has not re-appeared, MERS infections are of low incidence, and there are currently no vaccines for either of these related coronaviruses.

Compared to cellular immune assays, laboratory assays designed to measure humoral immune response based on production of immunoglobulins (Ig) against SARS-CoV-2 are logistically more feasible to implement across populations and to deploy at scale through commercial and reference laboratories. Additionally, serologic assays amenable to standardization through quality control programs (i.e., regulatory and compliance channels). The currently available assays with FDA EUA in the United States measure serum IgG, combined IgG and IgM, or total antibody (IgM, IgG, and IgA). These assays have been developed in several general categories: rapid tests, enzyme-linked immunosorbent assays (ELISA) and chemiluminescent assays, both of which could also be scaled to be highthroughput serological assays (HTSA), and lateral flow assays (LFA) 7 8 . For ELISA and M a n u s c r i p t chemiluminescent assays, results are calibrated using a signal cut-off value based on average signal intensity of positive and negative controls, thus setting a seropositivity threshold. SARS-CoV-2 serologic assay results are provided as binary (positive or negative) with an indeterminate value that is usually categorized as negative 1 . The targets for SARS-CoV-2 serologic assays include the nucleocapsid (N) protein, the spike (S) protein, the S1 region of the spike protein, and the receptor binding domain (RBD) of the S protein. While these assays are increasingly applied in seroprevalence studies and in clinical testing to assess past infection with SARS-CoV-2, there are limitations in the interpretation and application of qualitative antibody tests for clinical and public health decision making.

Neutralization assays against SARS-CoV-2 are a functional assessment of the ability of serum antibodies to prevent cell binding, entry, or other effects of the virus on the cell in vitro. In general, antibodies against the RBD or the S1 subunit are considered neutralizing 8 . Neutralization assays, such as the plaque-reduction neutralization test (PRNT) or microneutralization (MN) methods, have traditionally used live virus and are considered gold standards. However, these assays require Biosafety Level 3 (BSL-3) precautions and are generally labor-and resource-intensive to perform. BSL-3 sparing assays, such as pseudovirus neutralization, have been developed to overcome some of these challenges and have the potential for high throughput 9 10 . These assays are available in research laboratories globally, with only one neutralization assay commercially available for use in the United States 11 . However, the potential for these assays to be produced and used at high throughput in the commercial sector remains uncertain.

As of October 20 2020, there are no FDA EUA quantitative IgG assays available through commercial laboratories in the United States. There do not appear to be any quantitative assays in commercial use in China, Europe, or Asia. Two assays for semi-quantitative measurement of IgG in human serum and plasma have recently received FDA EUA 1 12 . In addition, several studies have used the signal to cut-off ratio from positive and negative controls as a semi-quantitative method. Although this approach provides an estimate of IgG levels, these tests generally lack the sensitivity and range of IgG quantitation needed to determine longevity and decay of IgG levels and correlation with neutralization assay titers.

Literature searches (using PubMed and Google Scholar and search terms IgG assays, neutralization assays, SARS-CoV-2, human) were conducted to identify English language publications from peer-reviewed journals, news items, and pre-prints from internet sites such as medRxiv 13 from January 2020 through October 20, 2020. Relevant publications were reviewed for mention of IgG, or neutralization assays for SARS-CoV-2, or both, and the methods of reporting assay results. Tables were populated for country where the laboratory test was performed, the setting of the study (i.e., clinical care surveillance or screening, convalescent plasma related, or vaccine candidate trials), number of individuals tested, inhouse or commercial assay, type of assay (i.e., ELISA, chemiluminescent, virus neutralization, micro-neutralization, pseudo-virus neutralization, other), and quantitation metric used to represent IgG and neutralization titers. M a n u s c r i p t

Based on review of the literature, applications for standardized quantitative IgG and neutralization assays include estimation of antibody longevity and decay in asymptomatic, symptomatic, ill, and recovered patients, evaluation and manufacturing of monoclonal antibody therapies, threshold estimations for correlates of protection (plotting of quantitative IgG values against neutralization titers), and vaccine immunogenicity and efficacy studies. Testing of donated convalescent plasma for antibodies would be considered a manufacturing step to determine IgG and neutralization titers prior to release of plasma for infusion therapy, offering another application for standardizing assays among laboratories involved in these trials.

Several published reports have described modifications of existing IgG serological assays to provide a quantitative or semi-quantitative measurement of anti-SARS-CoV-2 IgG antibody ( Table 1 ). The assay applications for these studies have included assessment of antibody levels in patients with clinical illness and evaluation of IgG antibody kinetics (decay) over time, with five reports describing studies performed as part of convalescent plasma donor therapy and five reports on early phase trials of vaccine candidates. There was a lack of standardization of the process of calibrating and reporting quantitative IgG results.

In reviewing current published reports of SARS-CoV-2 neutralization assays and the metrics used to report results (Table 2 ), there appears to be reasonable consistency across the sparse literature on this topic regarding the metrics of reporting of inhibition titers (either as 50% or 80% inhibitions) and serial dilutions.

This important step in determining serological correlates of protection for SARS-CoV-2 has been initiated by a limited number of groups.

Serum samples from three confirmed patients from France (multiple serial serum samples) indicated that the plaque reduction neutralization titers (PRNT 50 ) correlated in a linear fashion with IgG OD 450 values against S, S1 subunit, RBD, and N protein for one patient with mild and one patient with severe disease 14 . Jackson et al. reported strong correlation between binding and neutralization assays and between the live virus and pseudovirus neutralization assays 15 . In another small study, the OD levels in an IgG ELISA were reported to be statistically higher in severe/critical cases. Most of these patients, including those with mild non-pneumonic illness, developed detectable neutralizing antibodies provided the serum samples were collected beyond 28 days after illness. There was modest correlation of IgG ELISA OD between 1 and 2.5 with microneutralization titers between 1:10 and 1:80 (R=0.67) and PRN90 titers between 1:10 and 1:320 (R=0.73) 16 .

In a study of 187 sera from 107 patients from the Netherlands 8 , investigators reported a wide diversity in immunoglobulin assay performance in different scenarios and in correlation of assay results with virus neutralizing antibodies. One ELISA assay that detected total M a n u s c r i p t immunoglobulins against RBD performed best for assessing functional antibodies in different stages and severity of disease. This assay also demonstrated potential to set a cut-off indicating the presence of protective antibodies when correlated with plaque reduction neutralization assays.

A study of 175 patients from China who recovered from clinically mild disease 17 noted that neutralizing antibodies as measured by pseudovirus neutralization varied substantially, and included 10 patients in whom neutralizing antibodies were below the limit of detection.

A study of 12 plasma donors from New Mexico, USA 18 , noted variable neutralizing antibody titers among the donors with a median titer that was low; however there was a strong correlation by linear regression analyses of neutralizing antibody titers and IgG levels (rho=0.938, P<0.0001).

In a large study of 370 convalescent plasma donors 7 , the authors demonstrated that IgG assays predicted neutralizing activity in vitro and may thus serve to predict antiviral activity against SARS-CoV-2 in vivo, with RBD ELISA titers having a modest linear correlation (r 2 = 0·42) to neutralization titer, commensurate with the fact that the RBD is a principal target for neutralizing antibodies. As has been hypothesized, nucleocapsid ELISA titers showed no correlation with neutralization activity (r 2 = 0·09). Of note, lateral flow assay IgG densitometry measurements showed the poorest correlation with neutralization activity (r 2 = 0.22). The authors concluded that results of all quantitative serological assays correlate to some degree with neutralization activity and that high-throughput serology assay (HTSA) signal strength scores suggest presumptive ranges of neutralizing activity based on HTSA values.

Similarly, in a study of nearly 20,000 convalescent plasma donors screened at Mount Sinai Health System in New York City 19 , anti-spike protein binding titers correlated significantly with neutralization of SARS-CoV-2 in vitro; neutralizing activity above background was noted for approximately 50% of sera in the1:80-1:160 titer range of IgG, 90% of sera in the 1:320 range, and all sera in the 1:960-1:2880 range.

In a study of 109 convalescent plasma samples from 68 US patients reported by Salazar et al. 20 , a strong correlation was found between both plasma anti-RBD and anti-spike protein IgG titers, and in vitro micro-neutralization titer, although anti-RBD plasma IgG correlated slightly better than anti-spike protein IgG titer. The probability of a virus neutralization titer of ≥160 was 80% or greater with anti-RBD or anti-spike protein titers of ≥1:1350.

Evaluating the ability of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) to elicit immune responses 21 , Folegatti et al. found that titers from a pseudovirus neutralization assay and a SARS-CoV-2 neutralization assay correlated positively with other live neutralization assay titers and with an anti-RBD ELISA. They conclude that the correlation of neutralization assays with IgG quantitation indicates that, if confirmed, a standardized ELISA might be sufficient to predict protection, should neutralizing antibody also be shown to be protective in humans.

Ripperger et al 22 have correlated area under the curve IgG titers against RBD with neutralization assays and report an r of 0.84 for 153 samples from healthy volunteers and COVID-19 patients. PRNT90 values were determined as the last dilution by which 90% neutralization occurred. Antibody titers were quantified for RBD by quantifying area under the curve (AUC) across a serial dilution curve. M a n u s c r i p t

In addition, several studies have published quantitative IgG levels and neutralization titers in vaccine recipients with no attempt to assess correlation of these results. An mRNA vaccine candidate has been reported to elicit robust IgG titers consistently after the second dose 15 , along with neutralization titers in all 45 trial participants. Mulligan et al 23 reported on another RNA vaccine candidate; RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titers in sera increased with dose level and after a second dose. Geometric mean neutralizing titers reached 1.8-to 2.8-fold that of a panel of COVID-19 convalescent human sera. Logunov et al 24 reported on a trial of a vaccine candidate based on a non-replicating adenovirus 26 based vector wherein all 76 trial participants produced antibodies to the spike protein as well as neutralizing antibodies. Another vaccine candidate using the adenovirus based vector (Ad26.COV2.S) directed against the spike protein has been shown to elicit IgG and neutralization titers in a majority of trial participants 25 ; these investigators have reported ELISA results in ELISA units and neutralization assay results using wild type virus neutralizations as IC50 values.

Apart from one report of three individuals being protected from re-infection on a fishing vessel 26 , there are currently no data to estimate the level of neutralization activity that is needed to confer protective immunity based on clinical and epidemiologic studies of infection, recovery, and re-infection.

Efforts led by the U.S. government are underway to coordinate work across federal agencies, industry, and academic partners to standardize and validate SARS-CoV-2 antibody assays and their use in seroprevalence studies 27 . The World Health Organization has recognized the importance of this standardization 28 and has explicitly endorsed the need for standardization of assays used to: (1) measure antibody responses elicited by vaccination; (2) diagnose previous infection by SARSCoV-2; and (3) determine SARS-CoV-2 antibody content in COVID-19 convalescent plasma. Furthermore, WHO has recognized the challenges posed by a lack of knowledge regarding the need for standard antigen preparations to calibrate antibody binding assays.

Due to the rapidly evolving landscape of published and preprint literature on SARS-CoV-2, it is possible that not all relevant reports were identified and reviewed for inclusion in this review. Similarly, visibility on efforts underway within countries, professional organizations, and laboratories is limited.

The lack of standardization and use of in-house developed serologic assays by different laboratories preclude comparison of results from the various studies being reported in the literature. This has implications for interpreting results across studies of SARS-CoV-2 infected patients and convalescent plasma, monoclonal antibody, and vaccine candidate trials. Gaps in knowledge and recommendations to expand the use of serologic assays for SARS-CoV-2 have been recently described 29 .

Regarding attempts at reporting quantitative IgG and neutralization assays, despite similar types of titers reported, there remains a need for validation and standardization of assay results due to variability in how these assays are developed and performed. Development of clear criteria regarding the appropriate use of quantitative versus qualitative serologic assays would also facilitate standardization of reporting and comparison across studies.

Correlating IgG levels (using quantitative metrics) with neutralization titers, as has been described for other viruses such as measles 30 is an essential step prior to describing threshold ranges of levels (with 95% confidence intervals) of IgG that would serve as a surrogate of protection when measured in isolation with no companion neutralization assay results. 2 These ranges could then be used to predict outcomes in patients, follow patients after recovery and for re-infection, and help understand the response to vaccination. Importantly, these data could provide insight on development of post-infection immunity and whether, if present, it correlates with a specific serologic response in terms of antibody type and titer.

This review highlights specific advances needed in three areas: validation and standardization of quantitative IgG and neutralization assays and estimation of serologic correlates and thresholds of protection.

For quantitative IgG assays, there is a need to (a) further define various viral protein targets; (b) validate targets with respect to quantification and standardization of the source of these targets (proteins and plasmids); (c) develop international standards for the quantitation of IgG so that results from different assays can be compared; (d) develop and deploy standardized assays at scale in sufficient numbers of persons in all age groups, races and ethnicities, with an emphasis on disproportionately affected and special populations, to allow generalizability of results; and (e) describe distinctions in viral protein targets from natural infection vs. vaccination or monoclonal antibody therapy.

For neutralization assays, there is a need to: (a) further define viral protein targets of neutralization activity, such as the receptor binding domain of the spike protein; (b) develop international standard metrics for reporting neutralization titers; and (c) develop and deploy BSL-3 sparing assays, such as pseudo-virus neutralization assays, at scale as noted above, to allow generalizability of results.

For estimating serologic correlates of protection there is a need to estimate thresholds for protection of neutralization titers and plot quantitative IgG values against neutralization titers. These studies would ideally be performed at scale as described above and sufficiently powered to allow for estimating thresholds in various populations. Furthermore, it would be important for studies to be representative of the general population to allow generalizability of results. Inclusion of persons that are demographically diverse (e.g., age, sex, race/ethnicity) and that represent the spectrum of disease (asymptomatic to ill), along with persons from disproportionately affected populations, will permit greater generalizability.

The ideal future state would be to first develop and validate quantitative IgG assays with similar protocols. This would be followed closely by at-scale testing of populations using quantitative IgG assays to determine surrogate correlates of protection in recovering patients and possible re-infections; estimate antibody kinetics and longevity of humoral immune responses post-illness (using IgG as the surrogate rather than neutralization assays); and vaccine efficacy (using IgG as the surrogate rather than neutralization assays or infection rates). These laboratory-based studies must be correlated with observed levels of protection against infection and re-infection in clinical and epidemiological studies.

Ongoing intragovernmental among CDC, FDA, National Institutes of Health (NIH), and National Institutes of Standards and Technology (NIST)) collaboration, combined with international cooperation and development of public-private partnerships (e.g., with the clinical laboratory community, convalescent serum repositories, and commercial manufacturers of serologic laboratory assays, vaccines, and monoclonal antibodies for therapeutic and prophylactic use), can foster standardization, development, and deployment of assays at-scale and thus facilitate achievement of these goals. M a n u s c r i p t M a n u s c r i p t Table 1 . SARS-CoV-2 Immunoglobulin G "quantitation" as presented in recent studies (From January 2020 to October 20, 2020) among persons with SARS-CoV-2 infection, convalescent plasma donors, and vaccine trial participants 

Coronavirus Disease 2019 (COVID-19) Emergency Use Authorizations for Medical Devices

Vaccines: correlates of vaccine-induced immunity

Correlates of protection induced by vaccination

The Immunobiology of SARS*

CoV-2: A New Song Recalls an Old Melody

A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. medRxiv

Serological Analysis of New York City COVID19 Convalescent Plasma Donors. medRxiv

An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Laboratory Corporation of America. LabCorp Launches New Neutralizing Antibody Test: Neutralizing Antibody Assay Could Be Used to Assist in Development of COVID-19 Vaccines and Plasma-Based Treatments

Siemens Medical Solutions USA I. SARS-CoV-2 IgG Assay: The Siemens Healthineers SARS-CoV-2 IgG (COV2G) Assay* is the first FDA EUA-authorized semi-quantitative assay to help clinicians assess the level of an individual's immune response over time

13. medRxiv: The Preprint Server for Health Sciences. COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in

SARS-CoV-2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in COVID-19 Patients

SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months

Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma. bioRxiv

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low Prevalence Communities and Reveal Durable Humoral Immunity

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial

Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate

The COVID-19 Serology Studies Workshop: Recommendations and Challenges

World Health Organization. Main outcomes of the meeting of the WHO Expert Committee on Biological Standardization held from 24 to 28

Serodiagnostics for Severe Acute Respiratory Syndrome-Related Coronavirus 2 : A Narrative Review

Calibration and Evaluation of Quantitative Antibody Titers for Measles Virus by Using the BioPlex 2200. Clin Vaccine Immunol

Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19

Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19

Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerging Microbes & Infections

Connecting clusters of COVID-19: an epidemiological and serological investigation

Antibody responses to SARS-CoV-2 in patients with COVID-19

Standardization of enzyme-linked immunosorbent assays for serosurveys of the SARS-CoV-2 pandemic using clinical and athome blood sampling. medRxiv

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

M a n u s c r i p t Table 2 . SARS-CoV-2 Neutralizing Antibody Assay quantitation as presented in recent studies (From January 2020 to October 20, 2020) A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t